EP
AMRX icon

Eversept Partners’s Amneal Pharmaceuticals AMRX Stock Holding History

Eversept Partners’s Portfolio AMRX Stock Details AMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-2,644,988
Closed -$11.2M – 59
2023
Q3 		$11.2M Sell
2,644,988
-2,620,263
-50% -$9.77M 0.94% 23
2023
Q2 		$16.3M Buy
5,265,251
+82,205
+2% +$175K 1.36% 19
2023
Q1 		$7.2M Buy
5,183,046
+4,352,086
+524% +$8.67M 0.5% 36
2022
Q4 		$1.65M Sell
830,960
-3,859,852
-82% -$8.65M 0.14% 51
2022
Q3 		$9.48M Sell
4,690,812
-803,468
-15% -$2.25M 0.82% 27
2022
Q2 		$17.5M Buy
5,494,280
+2,783
+0.1% +$10.1K 1.24% 25
2022
Q1 		$22.9M Sell
5,491,497
-949,075
-15% -$4.2M 1.76% 20
2021
Q4 		$30.9M Sell
6,440,572
-409,262
-6% -$2.04M 1.97% 16
2021
Q3 		$36.6M Buy
6,849,834
+1,225,109
+22% +$6.17M 2.53% 13
2021
Q2 		$28.8M Buy
5,624,725
+869,245
+18% +$4.94M 1.92% 21
2021
Q1 		$32M Buy
4,755,480
+3,577,327
+304% +$19.8M 2.41% 15
2020
Q4 		$5.38M Sell
1,178,153
-1,478,055
-56% -$6.55M 0.63% 34
2020
Q3 		$10.3M Buy
2,656,208
+1,769,621
+200% +$7.57M 2.29% 15
2020
Q2 		$4.22M Buy
+886,587
New +$3.65M 0.58% 31

Other funds holding AMRX

FI
Fosun International Hong Kong, China $399M AUM 16.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Eversept Partners's AMRX Position: Q4 2023 in Review

Eversept Partners sold out of Amneal Pharmaceuticals (AMRX) in Q4 2023, closing a stake of 2,644,988 shares — an estimated $11.2M sold.

Eversept Partners first reported a position in AMRX in Q2 2020 and held it in 14 quarters. The position peaked at $36.6M in Q3 2021. 153 funds tracked by Wall St. Rank hold AMRX as of Q4 2023.

  • Eversept Partners reported no remaining Amneal Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
  • Eversept Partners sold 2,644,988 Amneal Pharmaceuticals shares in Q4 2023, an estimated $11.2M.
  • Eversept Partners first reported a position in Amneal Pharmaceuticals in Q2 2020 and held it in 14 quarters.
  • Eversept Partners's Amneal Pharmaceuticals position peaked at $36.6M in Q3 2021.
  • 153 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q4 2023.

Based on Eversept Partners's 13F filing for Q4 2023, filed 14 Feb 2024.